Plasma levels of human atrial natriuretic peptide in patients with hypertensive diseases.
Three types of antihuman atrial natriuretic peptide antiserum were obtained. From the study of cross-reactivity to human atrial natriuretic peptide fragments, it was suggested that antisera-1, -2, and -3 are mostly specific to 1-28, 5-25, and the ring structure, respectively. The estimated values of this hormone were significantly lower in the order of antisera-1, -2, and -3. Moreover, high performance liquid chromatographic study showed that various types of fragments of atrial natriuretic peptide exist in human plasma. These findings suggested that the highly specific antiserum to 1-28 human atrial natriuretic peptide such as antiserum-1 should be used to estimate the 1-28 human atrial natriuretic peptide levels in human plasma. From the study by using antiserum-1, it was concluded that the plasma human atrial natriuretic peptide increased in essential hypertensives, and in patients with primary aldosteronism, chronic renal failure, and malignant hypertension. Regarding the pathophysiological significance of increased plasma atrial natriuretic peptide, it is unlikely that this plays an important role in the etiology of essential hypertension or other hypertensive diseases, because the plasma level of this hormone is elevated in these patients. The increase of plasma atrial natriuretic peptide level in these patients should be considered to be a secondary or compensatory reaction to high blood pressure.
D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood* / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D003429:Cross Reactions; D004039:Diet, Sodium-Restricted; D006801:Humans; D006973:Hypertension / Q000097:blood*; D010953:Plasma Volume / Q000187:drug effects; D011863:Radioimmunoassay / Q000379:methods; D012083:Renin / Q000097:blood
D000804:Angiotensin II; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012083:Renin